Monday, June 25, 2018

3 Growth Stocks to Buy and Hold for 25 Years

One of the best ways to profit with stocks is also one of the simplest: Find great companies, buy them, and then hold them for as long as you can. And while simple isn't always easy -- try holding a stock that falls by 40% during the next market downturn -- it has proven to be an excellent way to generate life-changing wealth.�

We challenged three investors to give us some seriously�long-term ideas with a simple question: "What's a stock to buy and hold for 25 years?" They came up with�CareTrust REIT Inc. (NASDAQ:CTRE),�Alphabet Inc.�(NASDAQ:GOOG)(NASDAQ:GOOGL), and�Visa Inc.�(NYSE:V).�

And when we asked them why, they really gave us something to get excited about. Here's why owning these three growth stocks could make you very happy for the next 25 years -- or even longer.�

A view of very tall trees from below.

Image source: Getty Images.

An unloved industry set for decades of growth

Jason Hall�(CareTrust REIT): Baby boomers are moving into retirement age in full force, with around 3 million turning 65 every year between now and 2029, when the youngest boomers reach Medicare eligibility. By 2030, there will be 80 million American seniors, around half of whom will be 80 or older.�

And even with advances in healthcare, better outpatient and in-home treatment and assistance, a substantial portion will find themselves in need of specialized healthcare and senior housing facilities, either on a temporary or permanent basis. And I think CareTrust, a small (but fast-growing) specialist, in owning those kinds of properties, could be a huge winner for investors.�

CareTrust currently owns just shy of 200 properties, more than double the 94 it had when it went public in 2014. This expansion has not only increased cash flows, but also decreased the concentration of those cash flows from its biggest tenants, lowering its risk profile while simultaneously growing investor returns. CareTrust has increased the payout of its quarterly dividend a remarkable 64% since the first payout in late 2014, and as a REIT -- real estate investment trust -- it is likely to continue increases so long as management continues growing the business and its cash flows.�With the steady growth in the older population set to last multiple decades, I'm counting on CareTrust's management to do just that.�

CTRE Dividend Chart

CTRE Dividend data by YCharts.

With a yield pushing 5% at recent prices and a major long-term trend set to drive steady growth, CareTrust is an ideal multidecade investment.�

Searching for a winning growth stock

Jordan Wathen (Alphabet):�As the telephone book of the modern era, Alphabet's Google business has a long runway for growth that should power earnings growth for decades to come.

Admittedly, I'm not sure what to make of the company's so-called "other bets," which include stakes in companies like Calico Labs, which is trying to find a solution to human aging, or Fiber, which is pushing the envelope for consumer internet speeds at an affordable price. Together, other bets posted an operating loss of $571 million in the most recent quarter, a drain on the $8.4 billion of operating income generated by the core Google advertising business.

But even if Alphabet's science projects turn out to be money losers forever, I believe Alphabet stock can still generate a market-beating return due to just the advertising businesses. Google and YouTube have something of a royalty in online commerce, collecting a fee every time an internet user views or clicks an advertisement served up by Google's network.

Best of all, search and video are two businesses that benefit from network effects. Each search trains Google to be better at delivering relevant content, while content creators on YouTube benefit from the contributions of others, which brings more traffic and video views. If there is one tech stock to buy and ignore for 25 years, Alphabet is it.�

This growth stock could "charge" higher over the next 25 years

Sean Williams (Visa): Set-it-and-forget-it stocks aren't easy to come by, but if you're looking to sock away a solid growth stock for the next 25 years for your own portfolio, or that of your children or grandchildren, I can't think of many better ideas than global payment processing giant Visa.

The beauty of Visa is a combination of its incredible U.S. market share, a high barrier to entry in payment processing, and a massive market opportunity overseas.

Back in 2006, WalletHub noted that Visa held a 42.5% market share in U.S. credit card network purchase volume, which was a little over 13% ahead of its next-closest rival. By 2016, Visa controlled almost 51% of U.S. network purchase volume, which is nearly 28% higher than the next-closest competitor, American Express. This dominant market share makes it the go-to for merchants in what could arguably be described as the most consumption-oriented market in the world.�

Visa and its relatively few competitors also benefit from a relatively high barrier to entry in credit processing. It takes quite a bit of capital to build the infrastructure needed to process and validate transactions, which removes a number of would-be competitors from the equation. Plus, Visa's rapport with merchants is an intangible that none of its peers, or prospective new entrants, can match. Might I add, this includes cryptocurrencies, which are considerably slower than Visa in terms of payment validation and transaction speed per second.

Visa is also intriguing because it's hardly tapped markets in Africa, the Middle East, and Southeast Asia. Somewhere in the neighborhood of 85% of the world's transactions are still conducted in cash, leaving plenty of opportunity for Visa to spread its wings.�

Ultimately, we're talking about a company that's practically impervious to recessions given that it's not a lender (unlike AmEx and a few of its peers), and therefore has no risk to credit delinquency. By focusing solely on being a payment-processing middleman, Visa has found a niche where it's been able to grow revenue every year for more than a decade. With a steadily growing dividend, healthy cash flow, and a reasonable expectation of approximately 10% revenue growth each year, Visa is a safe growth stock to sock away for the next 25 years.

Sunday, June 24, 2018

UGAIN (GAIN) Price Hits $0.0023 on Top Exchanges

UGAIN (CURRENCY:GAIN) traded flat against the U.S. dollar during the 1 day period ending at 23:00 PM E.T. on June 22nd. One UGAIN coin can now be purchased for about $0.0023 or 0.00000037 BTC on popular cryptocurrency exchanges including YoBit and CoinExchange. During the last week, UGAIN has traded up 59.4% against the U.S. dollar. UGAIN has a total market cap of $0.00 and approximately $2.00 worth of UGAIN was traded on exchanges in the last 24 hours.

Here is how other cryptocurrencies have performed during the last 24 hours:

Get UGAIN alerts: XRP (XRP) traded 6.7% lower against the dollar and now trades at $0.52 or 0.00008331 BTC. Ripple (XRP) traded down 6.8% against the dollar and now trades at $0.49 or 0.00008034 BTC. Stellar (XLM) traded 9.5% lower against the dollar and now trades at $0.20 or 0.00003320 BTC. TRON (TRX) traded 8.2% lower against the dollar and now trades at $0.0437 or 0.00000715 BTC. IOTA (MIOTA) traded down 11.8% against the dollar and now trades at $1.00 or 0.00016334 BTC. Tether (USDT) traded 0.1% higher against the dollar and now trades at $1.00 or 0.00016402 BTC. NEO (NEO) traded 9% lower against the dollar and now trades at $33.59 or 0.00549413 BTC. Binance Coin (BNB) traded 6.6% lower against the dollar and now trades at $15.58 or 0.00254864 BTC. VeChain (VET) traded down 9.5% against the dollar and now trades at $2.83 or 0.00046228 BTC. Ontology (ONT) traded 15% lower against the dollar and now trades at $5.23 or 0.00085468 BTC.

About UGAIN

UGAIN’s official Twitter account is @teamugain.

Buying and Selling UGAIN

UGAIN can be purchased on the following cryptocurrency exchanges: YoBit and CoinExchange. It is usually not possible to purchase alternative cryptocurrencies such as UGAIN directly using U.S. dollars. Investors seeking to trade UGAIN should first purchase Ethereum or Bitcoin using an exchange that deals in U.S. dollars such as Changelly, Coinbase or GDAX. Investors can then use their newly-acquired Ethereum or Bitcoin to purchase UGAIN using one of the aforementioned exchanges.

Wednesday, June 20, 2018

Top Gold Stocks For 2018

tags:NSP,NOC,RH,GHDX,MCC,DERM,

After a double-digit run-up in the last quarter of 2017, shares of�Wheaton Precious Metals (NYSE:WPM) dealt a heavy blow to investors when they nosedived in February alongside the broader market. The sell-off was clearly overdone, as the stock soon bounced back to regain all of its losses and more, swiftly closing the gap with peers Franco-Nevada (NYSE:FNV) and Royal Gold (NASDAQ:RGLD). As of this writing, Wheaton's up nearly 16% from its February bottom.

Does that make Wheaton Precious Metals stock a buy at current prices?

The silver lining

Because silver contributes a major chunk to Wheaton's revenues, declining silver production for the better part of 2017 kept investors on tenterhooks and drove the stock lower.�

Note that production here doesn't mean extraction of metals, as is typically the case with gold and silver miners. Wheaton, Royal Gold, and Franco-Nevada are precious metals streaming companies, which means they buy metals from third-party miners at discounted prices under streaming agreements in exchange for funding the miners upfront. In other words, these companies' sales are hit if their mining partners face production hurdles. Last year, for example, lower production from gold miner�Goldcorp's Penasquito mine hit Wheaton and Royal Gold, both of which have streaming agreements with Goldcorp.

Top Gold Stocks For 2018: Insperity, Inc.(NSP)

Advisors' Opinion:
  • [By Joseph Griffin]

    Shares of Insperity Inc (NYSE:NSP) have been given a consensus rating of “Buy” by the six analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $86.75.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Insperity (NSP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Insperity (NSP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Wells Fargo & Company MN trimmed its holdings in shares of Insperity Inc (NYSE:NSP) by 17.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 176,365 shares of the business services provider’s stock after selling 37,265 shares during the period. Wells Fargo & Company MN owned about 0.42% of Insperity worth $12,266,000 at the end of the most recent reporting period.

  • [By Ethan Ryder]

    Naturally Splendid Enterprises Ltd (CVE:NSP) insider Sead Hamzagic sold 141,500 shares of the company’s stock in a transaction dated Monday, June 11th. The stock was sold at an average price of C$0.21, for a total value of C$29,715.00.

Top Gold Stocks For 2018: Northrop Grumman Corporation(NOC)

Advisors' Opinion:
  • [By Logan Wallace]

    State of Wisconsin Investment Board boosted its holdings in Northrop Grumman (NYSE:NOC) by 1.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 151,723 shares of the aerospace company’s stock after buying an additional 2,063 shares during the period. State of Wisconsin Investment Board owned 0.09% of Northrop Grumman worth $52,970,000 at the end of the most recent reporting period.

  • [By Rich Smith]

    Orbital plans to begin ground-testing the rocket next year, by which time Orbital ATK will probably have been subsumed into new owner Northrop Grumman (NYSE:NOC). In anticipation of testing beginning, Orbital gave NGL an official name last month: OmegA.

  • [By Todd Shriber, ETF Professor]

    Code Pink takes issue with BlackRock's investments in aerospace and defense companies such as General Dynamics Corp.(NYSE: GD), Lockheed Martin Corp. (NYSE: LMT) and Northrop Grumman Corp. (NYSE: NOC).

  • [By Lisa Levin] Companies Reporting Before The Bell Thermo Fisher Scientific Inc. (NYSE: TMO) is projected to report quarterly earnings at $2.4 per share on revenue of $5.63 billion. Ford Motor Company (NYSE: F) is expected to report quarterly earnings at $0.41 per share on revenue of $37.16 billion. Twitter, Inc. (NYSE: TWTR) is projected to report quarterly earnings at $0.11 per share on revenue of $605.26 million. Comcast Corporation (NASDAQ: CMCSA) is expected to report quarterly earnings at $0.59 per share on revenue of $22.75 billion. General Dynamics Corporation (NYSE: GD) is estimated to report quarterly earnings at $2.52 per share on revenue of $7.6 billion. The Boeing Company (NYSE: BA) is expected to report quarterly earnings at $2.58 per share on revenue of $22.24 billion. Anthem, Inc. (NYSE: ANTM) is estimated to report quarterly earnings at $4.91 per share on revenue of $22.52 billion. Viacom, Inc. (NASDAQ: VIAB) is projected to report quarterly earnings at $0.79 per share on revenue of $3.04 billion. Northrop Grumman Corporation (NYSE: NOC) is estimated to report quarterly earnings at $3.61 per share on revenue of $6.61 billion. Rockwell Automation Inc. (NYSE: ROK) is expected to report quarterly earnings at $1.81 per share on revenue of $1.66 billion. Wipro Limited (NYSE: WIT) is projected to report quarterly earnings at $0.07 per share on revenue of $2.15 billion. The Goodyear Tire & Rubber Company (NASDAQ: GT) is expected to report quarterly earnings at $0.46 per share on revenue of $3.82 billion. Owens Corning (NYSE: OC) is projected to report quarterly earnings at $0.97 per share on revenue of $1.62 billion. T. Rowe Price Group, Inc. (NASDAQ: TROW) is estimated to report quarterly earnings at $1.71 per share on revenue of $1.29 billion. Dr Pepper Snapple Group, Inc. (NYSE: DPS) is expected to report quarterly earnings at $1.04 per share on revenue of $1.57 billion. Sirius XM Holdings Inc. (NASDAQ: SI
  • [By Max Byerly]

    TT International lessened its stake in Northrop Grumman (NYSE:NOC) by 40.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,047 shares of the aerospace company’s stock after selling 2,040 shares during the quarter. TT International’s holdings in Northrop Grumman were worth $1,063,000 as of its most recent filing with the SEC.

  • [By ]

    Moreno found similar patterns in Northrop Grumman (NOC) and Lockheed Martin (LMT) , both with pullbacks in February that seem to now be at a crossroads.

Top Gold Stocks For 2018: Restoration Hardware Holdings Inc.(RH)

Advisors' Opinion:
  • [By Isaac Pino, CPA]

    While much has been said about upscale furniture retailer RH's (NYSE:RH) soaring stock price recently, less attention has been paid to the story behind the company's radical overhaul.CEO Gary Friedman is making some intriguing contrarian bets for RH, pursuing experiential stores in an industry that's downsizing its bricks-and-mortar footprint. Meanwhile, Friedman's embracing a membership model, physical catalogs, and a premium market at a time when most everyone else is slashing costs, running promotions, and scrambling to move online.In the company's most recent conference call, Friedman shared his thoughts on the company's business model, the retail industry's herd mentality, and the habits and desires of furniture shoppers. Here are the three takeaways I found most interesting:

  • [By Max Byerly]

    Aperio Group LLC boosted its holdings in Restoration Hardware Holdings, Inc common stock (NYSE:RH) by 10.3% during the 1st quarter, HoldingsChannel.com reports. The fund owned 8,532 shares of the company’s stock after acquiring an additional 799 shares during the quarter. Aperio Group LLC’s holdings in Restoration Hardware Holdings, Inc common stock were worth $813,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

  • [By Garrett Baldwin]

    Today, Bill offers our readers a few of his favorites as Trump meets with Kim Jong Un.�Here's how to cash in regardless of how this summit turns out in the long run.

    The Top Stock Market Stories for Tuesday Last night, President Trump met North Korean leader Kim Jong Un in Singapore. This was the first meeting between a sitting American president and a North Korean leader. Following the agreement, analysts noted that the document signed by both parties included no concrete details for achieving denuclearization on the Korean Peninsula. Trump responded to criticism by saying he is fully confident that the Korean dictatorship will follow through. A U.S. district court will rule on whether to approve an $85 billion merger between AT&T Inc. (NYSE: T) and Time Warner Inc. (NYSE: TWX). The decision comes after about six weeks of debate in a courtroom. The ruling will likely have a significant impact on the proposed bid by The Walt Disney Co. (NYSE: DIS) for media giant Twenty-First Century Fox Inc.�(NYSE: FOXA). The Fed Open Market Committee kicks off its June meeting today. The U.S. central bank is expected to raise interest rates for the second time in 2018. On Wednesday, U.S. Federal Reserve Chair Jerome Powell will likely announce a hike of 0.25% to the benchmark rate to 2%. This would also mark the seventh hike since December 2015. Markets will be looking for clues during Powell's conference to determine how many additional times the Fed plans to raise interest rates during the final six months of the year. Three Stocks to Watch Today: RH, TSLA, GE Restoration Hardware Holdings Inc. (NYSE: RH) stock popped more than 20% in pre-market hours after the company reported very strong profits for the quarter. The retailer reported earnings per share of $1.33, well above the $1.02 anticipated by analysts. The company also reported a strong second-quarter outlook, news that reduced concerns about it falling short of revenue expectations. Tesla Inc. (Nasdaq: TS

Top Gold Stocks For 2018: Genomic Health, Inc.(GHDX)

Advisors' Opinion:
  • [By Logan Wallace]

    Genomic Health (NASDAQ:GHDX) – Equities researchers at Piper Jaffray issued their Q2 2018 earnings per share (EPS) estimates for shares of Genomic Health in a research report issued on Wednesday, May 2nd. Piper Jaffray analyst W. Quirk expects that the medical research company will post earnings of $0.06 per share for the quarter. Piper Jaffray has a “Hold” rating and a $33.00 price target on the stock. Piper Jaffray also issued estimates for Genomic Health’s Q3 2018 earnings at $0.11 EPS, Q4 2018 earnings at $0.14 EPS, FY2018 earnings at $0.44 EPS, Q1 2019 earnings at $0.16 EPS, Q2 2019 earnings at $0.18 EPS, Q3 2019 earnings at $0.12 EPS, Q4 2019 earnings at $0.15 EPS and FY2019 earnings at $0.62 EPS.

  • [By Brian Orelli]

    Shares of Genomic Health (NASDAQ:GHDX) are up 18.6% at 1:23 p.m. EDT after data from the Trial Assigning Individualized Options for Treatment (TAILORx) trial was presented at the American Society of Clinical Oncology meeting and published in The New England Journal of Medicine.

  • [By Brian Orelli]

    Cancer-test maker Genomic Health (NASDAQ:GHDX) started the year on a high note, posting double-digit revenue growth, and would have turned a profit if not for an $8.5 million�one-time charge for stopping development of the Oncotype SEQ Liquid Select test, which was announced on the last quarterly call.

  • [By Stephan Byrd]

    ELEKTA AB/ADR (OTCMKTS: EKTAY) and Genomic Health (NASDAQ:GHDX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

  • [By Shane Hupp]

    Genomic Health (NASDAQ: GHDX) and CareDx (NASDAQ:CDNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

  • [By Stephan Byrd]

    Genomic Health, Inc. (NASDAQ:GHDX) insider Kimberly J. Popovits sold 10,000 shares of Genomic Health stock in a transaction on Thursday, June 14th. The shares were sold at an average price of $48.89, for a total value of $488,900.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Top Gold Stocks For 2018: Medley Capital Corporation(MCC)

Advisors' Opinion:
  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Medley Capital (MCC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top Gold Stocks For 2018: Dermira, Inc.(DERM)

Advisors' Opinion:
  • [By Maxx Chatsko]

    Shares of skincare pharmaceutical specialist Dermira (NASDAQ:DERM) dropped nearly 23% today after the company hosted its investor and analyst day for 2018. Investors were none too thrilled with the presentations given -- and were only reminded about the stinging failure of a once-promising acne drug DRM01 in March. Shares slipped over 64% on that news.

  • [By WWW.GURUFOCUS.COM]

    For the details of Novo A's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Novo+A

    These are the top 5 holdings of Novo AInogen Inc (INGN) - 3,549,320 shares, 59.83% of the total portfolio. Acceleron Pharma Inc (XLRN) - 1,553,937 shares, 9.34% of the total portfolio. Dermira Inc (DERM) - 1,984,364 shares, 7.81% of the total portfolio. Shares added by 3.27%Corvus Pharmaceuticals Inc (CRVS) - 3,244,046 shares, 4.76% of the total portfolio. Akebia Therapeutics Inc (AKBA) - 2,225,000 shares, 4
  • [By Paul Ausick]

    Dermira Inc. (NASDAQ: DERM) traded down about 64% Monday and posted a new 52-week low of $8.95 after closing Friday at $25.16. The stock’s 52-week high is $38.39. Volume was about 40 times the daily average of around 615,000 shares. The company’s trial of a new acne treatment failed to meet the designated endpoints.

  • [By Chris Lange]

    Dermira Inc. (NASDAQ: DERM) watched its shares absolutely collapse early on Monday after the firm reported disappointing results from its late-stage trials in patients with acne vulgaris. Essentially, Dermira��s Phase 3 trials of the investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints.

  • [By Shane Hupp]

    Dermira (NASDAQ:DERM) has been given a $20.00 price target by Cantor Fitzgerald in a research note issued to investors on Thursday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 146.61% from the company’s previous close. Cantor Fitzgerald also issued estimates for Dermira’s FY2018 earnings at ($4.63) EPS.